The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease
Open accessAbstract
Purpose: Enzyme replacement therapy with rhGAA (Myozyme®) has lead to improved survival, which is largely attributable to improvements in cardiomyopathy and skeletal muscle function. However, crossreactive immunologic material-negative patients have a poor clinical response to enzyme replacement therapy secondary to high sustained antibody titers. Furthermore, although the majority of crossreactive immunologic material-positive patients tolerize or experience a downtrend in anti-rhGAA antibody titers, antibody response is variable with some crossreactive immunologic material-positive infants also mounting high sustained antibody titers.Methods: We retrospectively analyzed 34 infants with Pompe disease: 11 crossreactive immunologic material-negative patients, nine high-titer crossreactive immunologic material-positive patients, and 14 low-titer crossreactive immunologic material-positive patients. Clinical outcome measures were overall survival, ventilator-free survival, left ventricular mass index, Alberta Infant Motor Scale score, and urine Glc4 levels.Results: Clinical outcomes in the high-titer crossreactive immunologic material-positive group were poor across all areas evaluated relative to the low-titer crossreactive immunologic material-positive group. For the crossreactive immunologic material-negative and high-titer crossreactive immunologic material-positive groups, no statistically significant differences were observed for any outcome measures, and both patient groups did poorly.Conclusions: Our data indicate that, irrespective of crossreactive immunologic material status, patients with infantile Pompe disease with high sustained antibody titer have an attenuated therapeutic response to enzyme replacement therapy. With the advent of immunomodulation therapies, identification of patients at risk for developing high sustained antibody titer is critical.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease
Kishnani, P. S., Corzo, D., Nicolino, M., Byrne, B., Mandel, H., Hwu, W. L., Leslie, N., Levine, J., Spencer, C., McDonald, M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000251268.41188.04 · Cited by 781
Self-citationA Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease
van der Ploeg, A. T., Clemens, P. R., Corzo, D., Escolar, D. M., Florence, J., Groeneveld, G. J., Herson, S., Kishnani, P. S., Laforet, P., Lake, S. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909859 · Cited by 745
Self-citationEnzyme-Replacement Therapy in Mucopolysaccharidosis I
Kakkis, E. D., Muenzer, J., Tiller, G. E., Waber, L., Belmont, J., Passage, M., Izykowski, B., Phillips, J., Doroshow, R., Walot, I., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101183440304 · Cited by 667
Kishnani, P. S., Hwu, W.-L., Mandel, H., Nicolino, M., Yong, F., & Corzo, D. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2005.11.033 · Cited by 598
Self-citationvan den Hout, H. M. P., Hop, W., van Diggelen, O. P., Smeitink, J. A. M., Smit, G. P. A., Poll-The, B.-T. T., Bakker, H. D., Loonen, M. C. B., de Klerk, J. B. C., Reuser, A. J. J., et al. (2003) · Pediatrics · doi:10.1542/peds.112.2.332 · Cited by 555
Motor Assessment of the Developing Infant
Piper, M. C., & Darrah, J. (1994) · Medical Entomology and Zoology · Cited by 498
Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants
Kishnani, P. S., Goldenberg, P. C., DeArmey, S. L., Heller, J., Benjamin, D., Young, S., Bali, D., Smith, S. A., Li, J. S., Mandel, H., et al. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.08.003 · Cited by 383
Self-citationAmalfitano, A., Bengur, A. R., Morse, R. P., Majure, J. M., Case, L. E., Veerling, D. L., Mackey, J., Kishnani, P., Smith, W., McVie-Wylie, A., et al. (2001) · Genetics in Medicine · doi:10.1038/gim200127 · Cited by 347
Self-citationEarly Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease
Kishnani, P. S., Corzo, D., Leslie, N. D., Gruskin, D. J., van der Ploeg, A., Clancy, J. P., Parini, R., Morin, G., Beck, M., Bauer, M., et al. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e3181b24e94 · Cited by 343
Self-citation
Cited by
Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
Spampanato, C., Feeney, E., Li, L., Cardone, M., Lim, J., Annunziata, F., Zare, H., Polishchuk, R., Puertollano, R., Parenti, G., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202176 · Cited by 341
Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
Chirmule, N., Jawa, V., & Meibohm, B. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9340-y · Cited by 335
Desnick, R. J., & Schuchman, E. H. (2012) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090711-163739 · Cited by 269
Glycogen Metabolism and Glycogen Storage Disorders
Kanungo, S., Wells, K., Tribett, T., & El-Gharbawy, A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.10.59 · Cited by 200
Pratt, K. P. (2018) · Antibodies · doi:10.3390/antib7020019 · Cited by 96
Metadata
- Authors
- Banugaria, S. G., Prater, S. N., Ng, Y.-K., Kobori, J. A., Finkel, R. S., Ladda, R. L., Chen, Y.-T., Rosenberg, A. S., & Kishnani, P. S.
- Venue
- Genetics in Medicine
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 13
- Issue
- 8
- Pages
- 729-736
- ISSN
- 1098-3600 (ISSN-L)
- OpenAlex
- W2143609092
- Cited by
- 255
- References
- 32
- FWCI
- 10.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease. https://app.cochat.ai/papers/10.1097/gim.0b013e3182174703
- The paper
- Banugaria, S. G., Prater, S. N., Ng, Y.-K., Kobori, J. A., Finkel, R. S., Ladda, R. L., Chen, Y.-T., Rosenberg, A. S., & Kishnani, P. S. (2011). The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease. Genetics in Medicine. https://doi.org/10.1097/gim.0b013e3182174703
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.